Serán Bioscience

Serán Bioscience offers science-driven drug development solutions tailored to client needs.

Serán provides comprehensive drug product development, formulation, and manufacture to help overcome drug product challenges.

Serán takes a science-first approach in customizing drug product solutions for customers and is invested in a shared commitment to the rapid development of better therapeutics.

Dr. Erica Schlesinger’s career and leadership in pharmaceutical development earned her the AAPS Member Spotlight for June 2025.

Serán featured in Pharma Navigator's most recent summary article covering insights from Drug Delivery Day 2025

Proven strategies to enable robust First-in-Human products just six months

The discussion covers challenges and innovative approaches to developing complex and insoluble new drug candidates.

PharmSci360 will take place this year in New Orleans, LA

A nonprofit gathering of industry leaders in science and business focused on solving the most challenging drug development problems

Serán Bioscience leads a workshop at ADDF, where industry leaders discuss drug development challenges.

Serán Bioscience employs scientists and innovators focused on delivering medicines to patients faster.

Aslam Malik is a key leader at Serán Bioscience, contributing to innovation in pharmaceutical research and development.

Dan Smithey, Ph.D., is a key leader at Serán Bioscience, driving innovation in pharmaceutical research and development.

Erica Schlesinger, Ph.D., is a key leader at Serán Bioscience, contributing to pharmaceutical research and development.

Gaurav Aggarwal is a key leader at Serán Bioscience, driving innovation in pharmaceutical research and development.

Serán Bioscience combines advanced technology and scientific expertise to advance drug development.

Serán Bioscience uses science-first methodology and advanced drug delivery technologies to enable client medicines.

Serán Bioscience raises growth funding led by Biospring Partners to expand commercial operations. The contract development and manufacturing organization (CDMO) also retains support from existing investors Vivo Capital and Bain Capital Life Sciences, alongside contributions from its executive team. This investment aims to accelerate Serán’s commercial growth and operational capacity.

Sep 2026Drug Development and DeliveryNews article

Serán Bio raises $200 million to fund a new commercial manufacturing facility. The investment supports expansion into contract manufacturing, including capsules, blisters, and particle manufacturing. The company also develops devices, excipients, and modeling software for pharmaceutical production.

Sep 2024oindpnews.comNews article

Serán Bioscience secures a $200 million investment led by Bain Capital to construct its first commercial manufacturing facility. The funding supports expansion of contract development and manufacturing services for biopharmaceutical clients transitioning from clinical trials to commercial production. The company aims to address capacity bottlenecks in late-stage drug development.

Sep 2024Fierce PharmaNews article

Serán Bioscience secures over $200 million in growth funding from Bain Capital Life Sciences and Vivo Capital. The company uses the capital to develop a new commercial-scale manufacturing facility, expanding its production capabilities for biopharmaceuticals.

Sep 2024Contract PharmaNews article